ACOG supports over-the-counter availability of hormonal contraception as a way of reducing inconsistent use or nonuse. Data demonstrates that adherence rates are similar whether hormonal contraception is obtained via a prescriber or over-the-counter. In addition, the ACOG opinion is consistent with AAFP, AMA and APHA in its support of unrestricted access. ACOG does not call for age restrictions except that contraception should not be initiated before menarche.
General Points
DMPA and Progestin-only pills Exam and Lab Requirements (CDC – see ‘Learn More – Primary Sources’)
Combined Hormonal Contraception Exam and Lab Requirements (CDC – see ‘Learn More – Primary Sources’)
VTE WARNING – Category 3 or 4 (risks outweigh benefits or unacceptable risk for)
Other Issues to Consider Prior To Obtaining Over-The-Counter Combined Hormonal Contraception (Related to Estrogen Component)
ACOG Committee Opinion 788: Over-the-Counter Access to Hormonal Contraception
ACOG Statement on FDA Submission for Over-the-Counter Access to Contraception
ACOG: First Over-the-Counter Daily Contraceptive Pill Released
Are you an
ObG Insider?
Get specially curated clinical summaries delivered to your inbox every week for free
Please log in to ObGFirst to access this page
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan
You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site